Molecular targeting of the GK-GKRP pathway in diabetes

Bibliography

• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
   PubMed Web of Science ®Google Scholar
• Harris MI. Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998;21(Suppl 3):C11-14
   PubMed Web of Science ®Google Scholar
• Vinik AI, Vinik E. Prevention of the complications of diabetes. Am J Manag Care 2003;9:S63-80. quiz S81-4
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care 2007;30(Suppl 1):S4-S41
   PubMedGoogle Scholar
• Angelopoulos TP, Doupis J. Sodium-Glucose linked transporter 2 (SGLT2) inhibitors–fighting diabetes from a new perspective. Adv Ther 2014;31:579-91
   PubMed Web of Science ®Google Scholar
• Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414:1-18
   PubMed Web of Science ®Google Scholar
• Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 1990;39:647-52
   PubMed Web of Science ®Google Scholar
• Matschinsky FM. Glucokinase, glucose homeostasis, and diabetes mellitus. Curr Diab Rep 2005;5:171-6
   PubMedGoogle Scholar
• Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 2003;206:2049-57
   PubMed Web of Science ®Google Scholar
• Cardenas ML, Rabajille E, Niemeyer H. Suppression of kinetic cooperativity of hexokinase D (glucokinase) by competitive inhibitors. A slow transition model. Eur J Biochem 1984;145:163-71
   Google Scholar
• Storer AC, Cornish-Bowden A. Kinetic evidence for a ’mnemonical’ mechanism for rat liver glucokinase. Biochem J 1977;165:61-9
   PubMed Web of Science ®Google Scholar
• van Schaftingen E, Vandercammen A, Detheux M, et al. The regulatory protein of liver glucokinase. Adv Enzyme Regul 1992;32:133-48
   PubMedGoogle Scholar
• Vandercammen A, Van Schaftingen E. The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. Eur J Biochem 1990;191:483-9
   PubMedGoogle Scholar
• Anderka O, Boyken J, Aschenbach U, et al. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem 2008;283:31333-40
   PubMed Web of Science ®Google Scholar
• Detheux M, Vandercammen A, Van Schaftingen E. Effectors of the regulatory protein acting on liver glucokinase: a kinetic investigation. Eur J Biochem 1991;200:553-61
   Google Scholar
• Vandercammen A, Detheux M, Van Schaftingen E. Binding of sorbitol 6-phosphate and of fructose 1-phosphate to the regulatory protein of liver glucokinase. Biochem J 1992;286(Pt 1):253-6
   Google Scholar
• Shiota C, Coffey J, Grimsby J, et al. Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. J Biol Chem 1999;274:37125-30
   PubMed Web of Science ®Google Scholar
• Moore MC, Davis SN, Mann SL, et al. Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes Care 2001;24:1882-7
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Donahue EP, Shiota M. Defect in glucokinase translocation in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 2004;287:E414-23
   PubMed Web of Science ®Google Scholar
• Shin JS, Torres TP, Catlin RL, et al. A defect in glucose-induced dissociation of glucokinase from the regulatory protein in Zucker diabetic fatty rats in the early stage of diabetes. Am J Physiol Regul Integr Comp Physiol 2007;292:R1381-90
   Google Scholar
• Lu Y, Levin GV, Donner TW. Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab 2008;10:109-34
   PubMed Web of Science ®Google Scholar
• Kamata K, Mitsuya M, Nishimura T, et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004;12:429-38
   PubMed Web of Science ®Google Scholar
• Grewal AS, Sekhon BS, Lather V. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem 2014;14:585-602
   PubMed Web of Science ®Google Scholar
• Torres TP, Catlin RL, Chan R, et al. Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats. Diabetes 2009;58:78-86
   PubMed Web of Science ®Google Scholar
• Lloyd DJ, St Jean DJJr, Kurzeja RJ, et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 2013;504:437-40
   PubMed Web of Science ®Google Scholar
• Ashton KS, Andrews KL, Bryan MC, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept. J Med Chem 2014;57:309-24
   PubMed Web of Science ®Google Scholar
• Nishimura N, Norman MH, Liu L, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N’-arylpiperazine series. J Med Chem 2014;57:3094-116
   PubMed Web of Science ®Google Scholar
• St Jean DJJr, Ashton KS, Bartberger MD, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles. J Med Chem 2014;57:325-38
   Google Scholar
• Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-6
   PubMed Web of Science ®Google Scholar
• Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105-16
   PubMed Web of Science ®Google Scholar
• Hayward BE, Dunlop N, Intody S, et al. Organization of the human glucokinase regulator gene GCKR. Genomics 1998;49:137-42
   Google Scholar
• Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009;18:4081-8
   PubMed Web of Science ®Google Scholar
• Rees MG, Wincovitch S, Schultz J, et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 2012;55:114-22
   Google Scholar
• Kozian DH, Barthel A, Cousin E, et al. Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. Horm Metab Res 2010;42:502-6
   Google Scholar
• Rees MG, Ng D, Ruppert S, et al. Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes. J Clin Invest 2012;122:205-17
   Google Scholar
• Farrelly D, Brown KS, Tieman A, et al. Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci USA 1999;96:14511-16
   PubMedGoogle Scholar
• Grimsby J, Coffey JW, Dvorozniak MT, et al. Characterization of glucokinase regulatory protein-deficient mice. J Biol Chem 2000;275:7826-31
   PubMedGoogle Scholar
• Hariharan N, Farrelly D, Hagan D, et al. Expression of human hepatic glucokinase in transgenic mice liver results in decreased glucose levels and reduced body weight. Diabetes 1997;46:11-16
   PubMed Web of Science ®Google Scholar
• Ferre T, Riu E, Franckhauser S, et al. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 2003;46:1662-8
   PubMed Web of Science ®Google Scholar
• Pfefferkorn JA, Guzman-Perez A, Litchfield J, et al. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotini c acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 2012;55:1318-33
   PubMed Web of Science ®Google Scholar
• Mookhtiar KA, Umrani DA, Tambe S, et al. The liver-directed/pancreas-sparing pharmacokinetic profile of GKM-001, a glucokinase modulator with robust glucose lowering properties and low hypoglycemia risk [abstract 1130-P]. American Diabetes Association; Philadelphia, PA; 2012
   Google Scholar
• Bodvarsdottir TB, Wahl P, Santosh KC, et al. TTP355 a glucokinase activator [abstract 328-OR]. American Diabetes Association; San Francisco, CA; 2008
   Google Scholar
• Bebernitz GR, Beaulieu V, Dale BA, et al. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 2009;52:6142-52
   PubMed Web of Science ®Google Scholar
• Kazierad D, Pfefferkorn J, Bergman A, et al. The hepatoselective glucokinase activator (GKA) PF-04991532, lowers HbA1c after 12-weeks of dosing in patients with type 2 diabetes (T2DM). 73rd American Diabetes Conference; Chicago, IL; 2013
   Google Scholar
• Bedoya FJ, Wilson JM, Ghosh AK, et al. The glucokinase glucose sensor in human pancreatic islet tissue. Diabetes 1986;35:61-7
   Google Scholar
• Grossbard L, Schimke RT. Multiple hexokinases of rat tissues. Purification and comparison of soluble forms. J Biol Chem 1966;241:3546-60
   PubMed Web of Science ®Google Scholar
• Matschinsky FM, Ellerman JE. Metabolism of glucose in the islets of Langerhans. J Biol Chem 1968;243:2730-6
   PubMed Web of Science ®Google Scholar
• Sharma C, Manjeshwar R, Weinhouse S. Hormonal and dietary regulation of hepatic glucokinase. Adv Enzyme Regul 1964;2:189-200
   PubMedGoogle Scholar
• Sols A, Salas M, Vinuela E. Induced biosynthesis of liver glucokinase. Adv Enzyme Regul 1964;2:177-88
   Google Scholar
• Walker DG, Rao S. The role of glucokinase in the phosphorylation of glucose by rat liver. Biochem J 1964;90:360-8
   PubMed Web of Science ®Google Scholar
• Wilson JE. The hexokinase gene family. In: Matschinsky F, Magnuson MA, editors. Glucokinase and glycemic disease: from basics to novel therapeutics front diabetes. Karger; Basel: 2004. p. 18-30
   Google Scholar
• Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:162-4
   PubMed Web of Science ®Google Scholar
• Hattersley AT, Turner RC, Permutt MA, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307-10
   PubMed Web of Science ®Google Scholar
• Velho G, Froguel P, Gloyn A, et al. Maturity onset diabetes of the young type 2. In: Matschinsky F, Magnuson MA, editors. Glucokinase and glycemic disease: from basics to novel therapeutics front diabetes. Karger; Basel: 2004. p. 42-64
   Google Scholar
• Christesen HB, Jacobsen BB, Odili S, et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 2002;51:1240-6
   PubMed Web of Science ®Google Scholar
• Cuesta-Munoz AL, Huopio H, Otonkoski T, et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 2004;53:2164-8
   PubMed Web of Science ®Google Scholar
• Glaser B, Kesavan P, Heyman M, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998;338:226-30
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Noordam K, Willemsen MA, et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 2003;52:2433-40
   PubMed Web of Science ®Google Scholar
• Grimsby J, Matschinsky FM, Grippo JF. Discovery and actions of glucokinase activators. In: Matschinsky F, Magnuson MA, editors. Glucokinase and glycemic disease: from basics to novel therapeutics front diabetes. Karger; Basel: 2004. p. 360-78
   Google Scholar
• Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301:370-3
   PubMed Web of Science ®Google Scholar
• Sarabu R, Bizzarro FT, Corbett WL, et al. Discovery of piragliatin–first glucokinase activator studied in type 2 diabetic patients. J Med Chem 2012;55:7021-36
   PubMed Web of Science ®Google Scholar
• Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010;95:5028-36
   PubMed Web of Science ®Google Scholar
• Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2560-6
   PubMed Web of Science ®Google Scholar
• Wilding JP, Leonsson-Zachrisson M, Wessman C, et al. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2013;15:750-9
   PubMed Web of Science ®Google Scholar
• O’Doherty RM, Lehman DL, Telemaque-Potts S, et al. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 1999;48:2022-7
   PubMed Web of Science ®Google Scholar
• Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012;55:781-9
   PubMed Web of Science ®Google Scholar
• Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008;40:161-9
   PubMed Web of Science ®Google Scholar
• Gaunt TR, Zabaneh D, Shah S, et al. Gene-centric association signals for haemostasis and thrombosis traits identified with the HumanCVD BeadChip. Thromb Haemost 2013;110:995-1003
   Google Scholar
• Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, et al. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet 2013;50:298-308
   Google Scholar
• Chambers JC, Zhang W, Sehmi J, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011;43:1131-8
   PubMed Web of Science ®Google Scholar
• Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010;42:684-7
   PubMed Web of Science ®Google Scholar
• Saleheen D, Soranzo N, Rasheed A, et al. Genetic determinants of major blood lipids in Pakistanis compared with Europeans. Circ Cardiovasc Genet 2010;3:348-57
   Google Scholar
• Chasman DI, Pare G, Mora S, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 2009;5:e1000730
   PubMed Web of Science ®Google Scholar
• Talmud PJ, Drenos F, Shah S, et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet 2009;85:628-42
   PubMed Web of Science ®Google Scholar
• Chasman DI, Pare G, Zee RY, et al. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet 2008;1:21-30
   PubMedGoogle Scholar
• Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010;42:142-8
   Google Scholar
• Chambers JC, Zhang W, Zabaneh D, et al. Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians. Diabetes 2009;58:2703-8
   PubMed Web of Science ®Google Scholar
• O’Seaghdha CM, Wu H, Yang Q, et al. Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrations. PLoS Genet 2013;9:e1003796
   Google Scholar
• Wu JH, Lemaitre RN, Manichaikul A, et al. Genome-wide association study identifies novel loci associated with concentrations of four plasma phospholipid fatty acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2013;6:171-83
   Google Scholar
• Coviello AD, Haring R, Wellons M, et al. A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation. PLoS Genet 2012;8:e1002805
   PubMed Web of Science ®Google Scholar
• Chen G, Bentley A, Adeyemo A, et al. Genome-wide association study identifies novel loci association with fasting insulin and insulin resistance in African Americans. Hum Mol Genet 2012;21:4530-6
   Google Scholar
• Lemaitre RN, Tanaka T, Tang W, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet 2011;7:e1002193
   Google Scholar
• Tang W, Basu S, Kong X, et al. Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study. Blood 2010;116:5032-6
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet 2008;82:1185-92
   PubMed Web of Science ®Google Scholar
• Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011;123:731-8
   PubMed Web of Science ®Google Scholar
• Umeno J, Asano K, Matsushita T, et al. Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2011;17:2407-15
   PubMed Web of Science ®Google Scholar
• Taylor KC, Lange LA, Zabaneh D, et al. A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARe) Consortium. Hum Mol Genet 2011;20:3525-34
   Google Scholar
• Yang Q, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010;3:523-30
   PubMed Web of Science ®Google Scholar
• Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009;5:e1000504
   PubMed Web of Science ®Google Scholar
• Kottgen A, Pattaro C, Boger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010;42:376-84
   PubMed Web of Science ®Google Scholar
• Liu CT, Garnaas MK, Tin A, et al. Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet 2011;7:e1002264
   PubMedGoogle Scholar
• Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324
   PubMed Web of Science ®Google Scholar
• Osman W, Okada Y, Kamatani Y, et al. Association of common variants in TNFRSF13B, TNFSF13, and ANXA3 with serum levels of non-albumin protein and immunoglobulin isotypes in Japanese. PLoS One 2012;7:e32683
   Google Scholar
• Franceschini N, van Rooij Frank JA, Prins Bram P, et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet 2012;91:744-53
   Google Scholar